{"entity":{"id":"nct06825494","kind":"trial","name":"Clinical Studies for the Treatment of Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Capecitabine, Oxaliplatin, Penpulimab and Tislelizumab in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.","summary":"Clinical Studies for the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06825494 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 194 participants planned, started 2025-04-08 and due to reach its primary completion in 2026-03. Interventions recorded: LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine, Tislelizumab+Oxaliplatin+Capecitabine, LM-108 injection 10mg/kg +penpulimab, LM-108 injection 600mg + penpulimab and enpulimab+ Oxaliplatin+Capecitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06825494","url":"https://clinicaltrials.gov/study/NCT06825494"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["capecitabine","oxaliplatin","penpulimab","tislelizumab"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06825494","phase":"1/2","setting":"An Open-label Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab + Chemotherapy in Patients With Advanced Solid Tumors - Cohort A","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT06825494","source":"https://clinicaltrials.gov/study/NCT06825494","fetchedAt":"2026-10-07T16:55:06.589Z","studySha256":"d3c488690cf8cac3c11a7dac33ee8f0aeb1fffdab0f77a57471d55c45bed99ac","overallStatus":"RECRUITING","lastUpdatePosted":"2025-12-18","leadSponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":194,"enrolmentType":"ESTIMATED","siteCount":32,"recruitingSiteCount":2,"countries":["China"]}],"started":"2025-04-08","startedType":"actual","enrolled":194,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06825494/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"},{"id":"penpulimab","kind":"drug","name":"Penpulimab","route":"/drugs/penpulimab/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}]}}